Tag: Avacopan

For decades, vasculitis treatment relied heavily on broad immunosuppressants, often with severe side effects from long-term steroid use. In recent years, newer, more targeted medicines like avacopan for ANCA-associated vasculitis and benralizumab for EGPA have revolutionized therapy by offering a steroid-sparing approach. These advances provide hope for a future with more personalized and effective treatments and better quality of life for patients.

Affecting approximately 200 per million people, ANCA-associated vasculitis is a rare autoimmune condition with limited treatment options [1.2.1]. The key question for many patients is, **what is the new drug for vasculitis?** The answer lies in a targeted oral therapy called Avacopan.

According to NYU Langone Health, medication to reduce inflammation is the primary goal of most vasculitis treatment. A combination of corticosteroids and immune-suppressing drugs helps manage the condition, addressing the question of **what drug treats vasculitis?**.